Europe Epinephrine Market

Europe Epinephrine Market Size (2023 To 2028)

The Epinephrine market in the European region is predicted to be valued at USD 1.17 billion by 2028 from USD 740 million in 2023, growing at a CAGR of 9.59% from 2023 to 2028.

The growing incidence of allergic reactions due to insects, food, medicine, and other substances among the European population and increasing awareness programs are majorly driving the European epinephrine market growth. The growing awareness among people regarding the benefits of using epinephrine to save a life from severe allergic reactions by informing and educating the population about the auto-injectable epinephrine that helps to send the drug into the patient's body for immediate relief supports the growth of the European epinephrine market.

The rising usage of prefilled syringes is further fuelling the growth rate of the European epinephrine market. Most people using epinephrine for their allergic reactions prefer to use prefilled syringes to reduce the problems of over-dosing in administrating the drug. Especially, the people who are living far away from the hospitals and the older population are using these prefilled syringes based on doctor prescriptions.

The growing patient population suffering from chronic diseases such as asthma, cardiac arrest and others is supporting the growth of the epinephrine market in the European region. People who are suffering from asthma are using an epinephrin nasal spray to reduce allergic reactions in certain situations. Epinephrine hydrochloride is used by the patients during CPR to increase the rate of ROSC (return of spontaneous circulation) and survival rates.

The growing number of advancements in the manufacturing of epinephrine injections for various diseases is favoring market growth. Manufacturers and researchers are focused on the invention of a new form of epinephrine as a medication that can be taken by people without any severe complications. Researchers are focusing on the development of oral-based epinephrine in case of the absence of healthcare providers for taking an epinephrine injection. They are also manufacturing pen-based injections for the intake of epinephrine by the patients. Increasing research and development, increasing government support, and increasing product approvals of epinephrine are boosting the market’s growth rate in Europe.

Side effects after taking the epinephrine drug are the major factor that restrains the market growth. Some of the side effects are swelling, skin redness, nausea, vomiting, weakness, sweating and difficulty breathing, etc. Low-cost alternative to epinephrine injector is another factor that hampers the market growth. Lack of awareness about the injector, lack of product approvals, and lack of reimbursement policies are the other factor that impedes the market growth.

This research report on the Europe epinephrine market has been segmented and sub-segmented into the following categories.

By Type:

• Prefilled Syringe
• Auto-injector
• Ampoules and Vials

Based on type, the autoinjectors segment is predicted to hold the leading share of the European Epinephrine market during the forecast period.

By Application:

• Anaphylaxis
• Cardiac Arrest
• Superficial Bleeding
• Respiratory Disorders
• Others

Based on application, the cardiac arrest segment is predicted to grow at the fastest CAGR during the forecast period.

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Based on the distribution channel, the hospital pharmacies segment is estimated to have notable growth during the forecast period in the European Epinephrine market.

By Country:

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

Geographically, the European region accounted for the second largest share of the worldwide market in 2022 and is predicted to witness a notable CAGR during the forecast period owing to increasing awareness about the epinephrine drug and increasing healthcare expenditure. In Europe, epinephrine combined with Articaine is used as a numbing formula before dental procedures. Additionally, in Europe, an epinephrine nasal spray has been introduced as an alternative to auto-injectors for anaphylaxis disorder which is a potentially life-threatening allergic reaction. It can be caused in a few seconds or minutes after exposure to something the person is allergic to. Some of them are peanuts or bee stings etc. Nearly 4 percent of the population is suffering from an anaphylactic disorder in Europe.

The UK market is predicted to capture a substantial share of the European market during the forecast period owing to the increasing availability of the epinephrine autoinjector and drugs in online and offline pharmacies with medical prescriptions. The government of the UK provides several measures in epinephrine production and distribution which helps the population suffering from some allergic reaction in their daily life.

The German market is another noteworthy regional market in Europe and is anticipated to grow at a promising CAGR during the forecast period. The growth of the German market is majorly driven by the increasing number of pharmaceutical companies manufacturing epinephrine injectors. Most of the schools in Germany have epinephrine drugs which are used by children in immediate action to prevent any critical situations when children have allergic reactions to drugs or to any other substance.

KEY MARKET PLAYERS:

Mylan NV, ALK-Abelló A/S, Teva Pharmaceutical Industries Ltd, Adamis Pharmaceuticals Corporation and Lincoln Medical Limited are some of the key players in the European Epinephrine market.